World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
42831
World Ranking
6745
National Ranking
3561

Overview

Laura J. Esserman is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. Within these fields, their work addresses oncology, cancer research, radiology, nuclear medicine, medical imaging, pulmonary and respiratory medicine, as well as pathology and forensic medicine.

The scientist's research covers a range of main topics, including breast cancer treatment studies, cancer genomics and diagnostics, radiomics and machine learning in medical imaging, HER2/EGFR in cancer research, advanced breast cancer therapies, breast lesions and carcinomas, and cancer immunotherapy and biomarkers.

Frequent co-authors collaborating with Laura J. Esserman include Christina Yau, Laura van 't Veer, Gillian L. Hirst, Nola M. Hylton, and Angela DeMichele.

Their publications are commonly found in notable venues such as Cancer Research, Journal of Clinical Oncology, npj Breast Cancer, Annals of Surgical Oncology, and bioRxiv (Cold Spring Harbor Laboratory).

Some of their recent papers include:

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement, 2020, Nature Reviews Clinical Oncology
  • Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival, 2020, Annals of Oncology
  • Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial, 2021, Cancer Cell
  • Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies, 2022, Cancer Cell

Best Publications

  • Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

    Koei Chin;Sandy DeVries;Jane Fridlyand;Paul T. Spellman

  • Whole-genome analysis informs breast cancer response to aromatase inhibition

    Matthew J. Ellis;Li Ding;Dong Shen;Jingqin Luo

  • Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

    Jayant S Vaidya;Jayant S Vaidya;Frederik Wenz;Max Bulsara;Jeffrey S Tobias

  • Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

    Jayant S Vaidya;David J Joseph;Jeffrey S Tobias;Max Bulsara

  • I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

    AD Barker;CC Sigman;GJ Kelloff;NM Hylton

  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

    James L. Khatcheressian;Patricia Hurley;Elissa Bantug;Laura J. Esserman

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Rethinking screening for breast cancer and prostate cancer

    Laura Esserman;Yiwey Shieh;Ian Thompson

  • Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Matthew J. Ellis;Vera J. Suman;Jeremy Hoog;Li Lin

  • Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement

    Laura J. Esserman;Ian M. Thompson;Brian Reid

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

    Orit Rozenblatt-Rosen;Aviv Regev;Aviv Regev;Aviv Regev;Philipp Oberdoerffer;Tal Nawy

  • Addressing overdiagnosis and overtreatment in cancer: a prescription for change

    Laura J Esserman;Ian M Thompson;Brian Reid;Peter Nelson

  • Leukocyte composition of human breast cancer

    Brian Ruffell;Alfred Au;Hope S. Rugo;Laura J. Esserman

  • Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.

    Laura Esserman;Nola Hylton;Leila Yassa;John Barclay

  • Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

    Nola M. Hylton;Jeffrey D. Blume;Wanda K. Bernreuter;Etta D. Pisano

  • Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

    Laura J. Esserman;Donald A. Berry;Angela DeMichele;Lisa Carey

  • Breast Cancer Growth Prevention by Statins

    Michael J. Campbell;Laura J. Esserman;Yamei Zhou;Mark Shoemaker

  • Genomic andtranscriptional aberrations linked tobreastcancer pathophysiologies

    Koei Chin;Sandy DeVries;Jane Fridlyand;Paul T. Spellman

Frequent Co-Authors

Christina Yau
Christina Yau University of California, San Francisco
Laura J. van't Veer
Laura J. van't Veer University of California, San Francisco
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Angela DeMichele
Angela DeMichele University of Pennsylvania
Douglas Yee
Douglas Yee University of Minnesota
John W. Park
John W. Park University of California, San Francisco
Judy C. Boughey
Judy C. Boughey Mayo Clinic
Dan H. Moore
Dan H. Moore University of California, San Francisco
Kathy S. Albain
Kathy S. Albain Loyola University Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but seeking flexible educational options, several online degree pathways can help you build a rewarding career in healthcare. For those passionate about preventive health and wellness, a nutrition bachelor degree online offers foundational skills in dietary science and public health, opening avenues in clinical, community, or wellness settings.

Aspiring healthcare leaders can consider cahme-accredited online Master of Healthcare Administration (MHA) programs, which provide rigorous academic standards and industry recognition essential for managerial roles. Registered nurses aiming to advance without clinical requirements can enroll in online rn-bsn programs without clinicals, streamlining their education to fit busy schedules.

For those wanting to achieve the highest level in nursing, the shortest dnp program online enables working professionals to earn a Doctor of Nursing Practice with minimal disruption. Each of these pathways offers flexible entry into in-demand careers, allowing you to tailor your education to your goals and lifestyle.

Best Scientists Citing Laura J. Esserman

Trending Scientists

Recently Published Articles